Trial Profile

An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 09 Apr 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Golvatinib (Primary) ; Sorafenib
Indications Liver cancer
Focus Adverse reactions; Pharmacokinetics
Sponsors Eisai Inc

Most Recent Events

25 Aug 2017 Status changed from active, no longer recruiting to completed.
18 Aug 2016 The trial was completed in Belgium.
06 May 2016 The trial is completed in Spain (end date: 2015-04-30) and Italy (end date: 2015-06-30).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com